Palo Verde Hematology Oncology is a clinical research site located in Glendale, Arizona, United States 85304.
Crixeo Health Trust Score: 80/100 (GOOD). This profile has not yet been claimed by the site owner.
Palo Verde Hematology Oncology has participated in 14 clinical trials with 5 currently active.
Therapeutic areas: Metastatic Breast Cancer, Carcinoma, Non-Small-Cell Lung, Metastatic Castration-Resistant Prostate Cancer.
Sponsors: Pfizer, Celgene, Seagen, a wholly owned subsidiary of Pfizer.
Trust Score: 80/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
Palo Verde Hematology Oncology has a Crixeo Trust Score of 80/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Palo Verde Hematology Oncology has 14 clinical trials on record, with 5 currently active. Their work covers Metastatic Breast Cancer, Carcinoma, Non-Small-Cell Lung, Metastatic Castration-Resistant Prostate Cancer.
Yes — Palo Verde Hematology Oncology holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.